Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Novo Nordisk

Status: Completed

Conditions: Haemophilia A; Congenital Bleeding Disorder

Treatments: Drug: turoctocog alfa

Study type: Observational

Funder types: Industry

Identifiers

NCT03179748

U1111-1171-9845 (Other Identifier)

NN7008-4253

Details and patient eligibility

About

The trial is conducted in North America. The aim of the trial is to assess the safety of turoctocog alfa under conditions of routine clinical care in patients with haemophilia A in Mexico

Enrollment: 10 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
• Male and female patients with haemophilia A
• Age range is 0 years and above
• The decision to initiate treatment with commercially available turoctocog alfa has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study

Exclusion criteria

• Previous participation in this study. Participation is defined as having given informed consent in this study
• Known or suspected allergy to turoctocog alfa or related products
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Trial design

10 participants in 1 patient group

turoctocog alfa

Description:

Patients with haemophilia A

Treatment:

Drug: turoctocog alfa